Long-Term Effects of Secukinumab on Fatigue in Ankylosing Spondylitis
Study authors assessed the long-term effects of secukinumab on fatigue in patients with ankylosing spondylitis in the MEASURE 1 and MEASURE 2 trials.
Ankylosing spondylitis
Unmet Pain Management Needs Are Evident in Axial Spondyloarthritis
Investigators compared differences in pain reports between patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis to assess how pain sensitivity was associated with disease and health outcomes.
Enthesitis, Spinal Mobility Key Disability Drivers in axSpA
Investigators examined the long-term association between disease activity and disability in axSpA.
Inflammatory Burden High in Patients With Early Peripheral Spondyloarthritis
Researchers evaluated the prevalence of axial involvement in early peripheral spondyloarthritis and whether inflammation predicted relapse on treatment withdrawal.
Disease Activity Linked to Radiographic Progression in Axial Spondyloarthritis
Study authors determined the association between disease activity and the subsequent 2-year spinal radiographic progression in axial spondyloarthritis.
FDA to Review High-Concentration Biosimilar of Adalimumab
The FDA has accepted for review the BLA for AVT02 (Alvotech), a proposed biosimilar to adalimumab; AbbVie, with high concentration (100mg/mL) dosage forms.
Study Supports Safety, Efficacy of Tofacitinib in the Treatment of Ankylosing Spondylitis
Researchers evaluated the safety and efficacy of tofacitinib for the treatment of patients with ankylosing spondylitis.
Undiagnosed Axial Spondyloarthritis Prevalent Among Patients With Inflammatory Bowel Disease
Study authors evaluated the prevalence of axial spondyloarthritis in patients with inflammatory bowel disease in secondary care.
Gut Microbiome Changes Different in Ankylosing Spondylitis and IBD, Associated With Disease Activity
Researchers assessed whether the gut microbiome in ankylosing spondylitis and inflammatory bowel disease was different, and whether it correlated with disease activity.
Ixekizumab Superior to Placebo in Self-Reported Functioning and Health in Patients With Axial Spondyloarthritis
Researchers evaluated the effect of ixekizumab on self-reported functioning and health in patients with active nonradiographic axial spondyloarthritis.
-
Loading...
-
Loading...
Next post in Spondyloarthritis
